Management of hypertriglyceridemia in the diabetic patient

Current Diabetes Reports

Volumn 10, Issue 4, 2010, Pages 316-320

  Jialal, Ishwarlal ^a   Amess, William ^a   Kaur, Manpreet ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diabetes; Dyslipidemia; Fibrates; Hypertriglyceridemia; Niacin; Statins

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; ESTROGEN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; NICOTINIC ACID PLUS SIMVASTATIN; OMEGA 3 FATTY ACID; PLACEBO; PROTEINASE INHIBITOR; RETINOID; SIMVASTATIN; STEROID; TAMOXIFEN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; WARFARIN; ANTILIPEMIC AGENT; CLOFIBRIC ACID;

CLINICAL TRIAL; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG TARGETING; EXERCISE; FLUSHING; GASTROINTESTINAL DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; INTERNATIONAL NORMALIZED RATIO; LIFESTYLE MODIFICATION; LIVER FUNCTION TEST; MEDICAL DECISION MAKING; MYOSITIS; NUTRITIONAL HEALTH; PANCREATITIS; PATIENT EDUCATION; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; SMOKING CESSATION; TRIACYLGLYCEROL BLOOD LEVEL; COMPLICATION; DIABETES MELLITUS, TYPE 2; METABOLISM;

ANTILIPEMIC AGENTS; CLOFIBRIC ACID; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; INSULIN; NIACIN; TRIGLYCERIDES; HYPOLIPIDEMIC AGENTS;

EID: 77956394971     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-010-0124-4     Document Type: Review

References (24)

1. U.K. Prospective Diabetes Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex [no authors listed]. Diabetes Care 1997, 20:1683-1687.
2. Mazzone T, Chait A, Plutzky J: Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008, 371:1800-1819.
3. Hirany S, O'Byrne D, Devaraj S, Jialal I: Remnant-like particlecholesterol concentrations in patients with type 2 diabetes mellitus and end-stage renal disease. Clin Chem 2000, 46:667-672.
4. Turner RC, Millns H, Neil HA, et al.: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998, 316:823-828.
5. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, et al.: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta analysis. Lancet 2008, 371:117-125. The risk of adverse CVEs is reduced by statin therapy for diabetic individuals. This risk reduction applies whether or not the individual has a history of vascular disease.
6. Chait A, Brunzell JD: Chylomicronemia syndrome. Adv Intern Med 1992, 37:249-273.
7. McKenney JM, Sica D: Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia. Am J Health Syst Pharm 2007, 64:595-605.
8. Riyami N, Frohlich J: Extreme hypertriglyceridemia following intravenous heparin infusion. Clin Biochem 2008, 41:907-909.
9. Whayne T: Concerns about heparin therapy for hypertriglyceridemia. Arch Intern Med 2010, 170:108-109.
10. Cole R: Heparin treatment for severe hypertriglyceridemia in diabetic ketoacidosis. Arch Intern Med 2009, 169:1439-1441.
11. Sarwar N, Danesh J, Eiriksdottir G, et al.: Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115:450-458.
12. Ferns G, Keti V, Griffin B: Investigation and management of hypertriglyceridaemia. J Clin Pathol 2008, 61:1174-1183.
13. Brunzell JD: Clinical practice.Hypertriglyceridemia. N Engl JMed 2007, 357:1009-1017. Screening certain individuals with HTG for inherited lipid disorders can enable one to identify those who are at higher risk for premature CVD. The impact of various treatment modalities on aspects of the lipid profile is also addressed.
14. Jialal I, Bajaj M: Therapy and clinical trials: management of diabetic dyslipidemia. Curr Opin Lipidol 2009, 20:85-86.
15. The Coronary Drug Project Research Group: Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360-381.
16. Brown BG, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592.
17. Taylor AJ, Lee HJ, Sullenberger LE: The effect of 24 months of combination statin and extended-release niacin on carotid intimamedia thickness: ARBITER 3. Curr Med Res Opin 2006, 22:2243-2250.
18. Taylor AJ, Villines TC, Stanek EJ, et al.: Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361:2113-2122.
19. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418.
20. Rubins HB, Robins SJ, Collins D, et al.: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002, 162:2597-2604.
21. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study [no authors listed]. Lancet 2001, 357:905-910.
22. Keech A, Simes RJ, Barter P, et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
23. ACCORD Study Group, Ginsberg HN, Elam MB, et al.: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574. With respect to reducing cardiovascular risk, this study demonstrates that diabetic individuals do not benefit from the addition of a fibrate to statin therapy.
24. Scott R, O'Brien R, Fulcher G, et al.: Effects of fenofibrate treatment on cardiovascular disease risk in9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009, 32:493-498.